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Bladder cancer is a common cancer with approximately 50 000
new incidents per year in the United States (Wingo et al, 1999).
The most frequent bladder cancer form is transitional cell carci-
nomas (TCCs), which in most cases occur as benign papillomas,
with superficial recurrence in approximately 35% of the cases and
progression to an invasive life-threathening cancer in 15%. A char-
acteristic molecular feature of bladder cancer is a varying genomic
instability. This is most often observed as loss of heterozygosity
(LOH), dominated by LOH of parts of chromosome 9 in the early
stages (Cairns et al, 1993; Keen et al, 1994; Ruppert et al, 1993),
LOH of 3p21–25 (Presti et al, 1991), 4q33–34 (Polacik et al,
1995), 8p21 (Knowles et al, 1993), 17p11–13 (Presti et al, 1991)
and 18q21.3 (Brewster et al, 1994) in high stages, and frequent
mutations in p53 and Rb (Baker et al, 1989; Miyamoto et al, 1995;
Taylor et al, 1996). High frequency of LOH at the MLH1 and
MSH2 loci was previously shown in clinical bladder cancer
samples (Christensen et al, 1998). Several studies also report
microsatellite instability in TCC’s (Christensen et al, 1998;
Gonzales-Zulueta et al, 1993; Li et al, 1996; Orlow 
et al, 1994). Microsatellite instability is frequently observed in
tumour cells from patients with hereditary nonpolyposis colorectal
cancer (HNPCC), but is also observed in a significant subset of
sporadic colon, gastric, ovarian, endometrical and small cell lung
cancers (Arzimanoglou et al, 1998; Lothe, 1997). This instability
can in most cases be connected to mutations in genes involved in
the postreplicative mismatch repair system (for review see
Buermeyer et al, 1999; Kolodner and Marsischky, 1999; Yu et al,
1999). Bladder cancer is not part of the tumour spectrum of
HNPCC. The observed microsatellite instability in bladder cancer
is rarely of the ‘ladder’ type as seen in HNPCC but more often an
occurrence of a few extra bands or band shifts (Christensen et al,
1998). Another inactivation mechanism of the mismatch repair
system, observed in a significant percentage of sporadic colon
cancers, is promoter hypermethylation of the mismatch repair gene
MLH1 (Ghimenti et al, 1999; Toyota et al, 1999). 
Several studies have shown that the mispair recognition in
human postreplicative mismatch repair is due to two separate
heterodimers, the MSH2-MSH6 (mutSα ) – and the MSH2-MSH3
(mutSβ ) complexes. It seems that the two heterodimers have some
overlapping affinity. MSH2-MSH6 recognizes base-base mispairs
and small insertion-deletion loops, whereas MSH2-MSH3 recog-
nizes small and larger insertion-deletion loops (Genschel et al,
1998; Umar et al, 1998a or b; Umar et al, 1994). The mispair
recognition is followed by binding of the heterodimer complex,
MLH1-PMS2 (mutLα ) to the mutS complex (Gu et al, 1998;
Habraken et al, 1998). Recent studies show that other heterodimer
complexes exist and may play a part in the repair process (Wang 
et al, 1999). 
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The observed microsatellite instability and the frequent
occurence of mutations in p53 and RB in TCCs indicate that
mismatch repair deficiency could be involved in the progression of
bladder cancer. 
To investigate this hypothesis we tested the functional status of
the mismatch repair system in extracts from urothelial cancer cell
lines and clinical bladder cancer samples using a DNA heterodu-
plex repair assay (Thomas et al, 1995). The functional analysis
was combined with analysis for microsatellite instability, expres-
sion of the mismatch repair genes MSH2, MSH3, MSH6, PMS1,
PMS2, and MLH1, by RT-PCR, Western blotting analysis and
immunohistochemical staining for detection of the MLH1, MSH2
and PMS2 proteins. 
MATERIALS AND METHODS 
Cell lines 
The following cell lines were used in this study: TK6 a lymphoblas-
toid cell line. HCV29, HU609, SW780, RT4, HT1376, J82 and
T24, all bladder cancer cell lines. HCT116 and HCT15 both
colorectal cancer cell lines. The cell lines SW780, RT4, HT1376,
J82, T24, HCT116 and HCT15 were obtained from the American
Type Culture Collection (ATCC). HCV29 and HU609 were
obtained from the Fibiger Instituttet, Copenhagen, Denmark. TK6
and HCT15 were cultured in RPMI supplemented with 10% fetal
bovine serum. T24, HCT116 and RT4 were cultured in McCoy
media supplemented with 10% fetal bovine serum. HT1376 and
J82 were cultured in MEM with 10% fetal bovine serum. All media
were obtained from Life Technologies Inc., USA. 
Tissue samples 
Normal bladder tissue was obtained as biopsies from patients with
benign prostatic hypoplasia and urinary incontinence. Tissue
samples of transitional cell carcinomas were collected fresh from
surgery and immediately put on ice. The tissue samples were
disintegrated, permanently embedded in icecold isotonic buffer
(Thomas et al, 1995), and then moved through a 100 micron filter
(PGC Scientific, Maryland, USA) to ensure single cell preparation
and to minimize bladder wall contamination. 
At this stage an aliquot of cells was stored in guadinium thio-
cyanate for RNA preparation. The rest of the cells were used to
prepare extracts. 
Preparation of cytoplasmic protein extract 
The procedure for preparation of cytoplasmic protein extract from
cell lines is described in detail in (Thomas et al, 1995). To prepare
extract from bladder tissue samples, the filtered cells were washed
in 10 ml ice cold isotonic buffer (Thomas et al, 1995) and
centrifuged at 500 × g for 5 min at 4˚C. The isotonic buffer was
removed and the cells resuspended in 10 ml icecold hypotonic
buffer (Thomas et al, 1995) and centrifuged at 500 × g for 5 min at
4˚C. The hypotonic buffer was removed and the cells resuspended
in hypotonic buffer at a cell concentration of approximately 108
cells/ml. The cells were incubated on ice for 15 min, then
disrupted using a 2 ml Dounce homogenizer. It is important that
only approximately 80% of the cells are broken to minimize the
amount of histones in the extract. The broken cells were moved 
to an Eppendorf tube and incubated on ice for 15 min, and
centrifuged at 2000 × g for 5 min at 4˚C. The supernatant was
moved to a new Eppendorf tube and centrifuged at 12 000 × g for
5 min at 4˚C. The extract was aliquoted and immediately frozen 
at –80˚C. 
SV40 T-antigen dependent replication 
Approximately 100 µ g of crude cell extract was used in the
replication assay (Roberts and Kunkel, 1993). The assay was
performed using a SV40 Large T-antigen Replication Assay Kit
(CHIMERx, Milwaukee WI, USA) according to the manufac-
turer’s instructions. 
Heteroduplex repair assay 
The assay is described in detail in Thomas et al (1995), and
measures the strand-specific repair of mismatches in M13mp2
DNA. DNA substrates used contain a nick in the minus strand to
direct the mismatch repair to this strand and different types 
of mismatches in the lacZα -complementation reporter gene.
Introduction of an unrepaired mismatch substrate into an E. coli
strain defective in mismatch repair (mutS strain) yields blue, white
and mixed blue/white M13 plaques in a specific reproducible ratio.
Mismatch repair activity in the extract to be tested is detected by a
reduced percentage of mixed colour plaques and an increase in the
percentage of plaques having the colour encoded by the minus
strand relative to the unrepeared control. Mismatch repair effi-
ciency is calculated in percentage as 100 × (1 – [% mixed plaques
in the experimental sample / % mixed plaques in the mock treated
sample]). Repair values between 0 and 10% represent experi-
mental fluctuation in this assay. 
Microsatellite analysis 
For microsatellite analysis of cell lines, single cell clones were
obtained by increasing dilution into 96-well microtitre plates.
When nearly confluent, individual clones were subcultured in 75
ml flasks for ~ 15 generations before harvesting. Approximately
50 ng of DNA from each pool were used in PCR reactions using
HEX or FAM end-labelled primers. The PCR products was
analysed on an ABI 377 sequence analyser using Gene Scan soft-
ware version 2.1. The following microsatellite loci were analysed:
Mononucleotide repeat: BAT26. Dinucleotide repeat: D2S119,
D5S404, D8S255, D17S261. Tetranucleotide repeat: RB1. 
Western blotting 
The cell extracts used for Western blotting were similar to the
extract used in the mismatch repair assays. Ten µ g crude cell
extract was reduced by adding 0.5 M DTT, denatured at 70˚C 
for 10 min and applied to a 10% polyacrylamide gel (NuPage, 
Bis-Tris Gel, Novex). 
Ten µ l diluted protein marker (ECL protein molecular marker,
Amersham) were used. The samples were electrophoresed at 200
V for 50 min in an X-CELL system (Novex). Then the proteins
were transferred to a PVDF membrane at 30 V for 1 hour followed
by blocking for 1 h. The membrane was subsequently washed in 3
× 10 min in PBS buffer pH 7.4 + 0.1% Tween 20. The membrane
was incubated with antibodies against MLH1, MSH2 or PMS2
overnight at 4˚C. The membrane was then washed 3 × 10 min in570 T Thykjaer et al 
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PBS buffer pH 7.4 + 0.1% Tween 20, followed by incubation for
1 h with a biotinylated streptavidin horseradish peroxidase
complex. The detection reagent (ECL + Western blotting detection
system, Amersham) was applied for 5 min. Finally, the membrane
was wrapped in plastic, sealed, and scanned in a Phosphorimager,
STORM 840 (Molecular Dynamics, Amersham Pharmacia,
Sweden). 
Immunohistochemistry 
Immunoperoxidase staining for MLH1, MSH2 and PMS2 in
formalin-fixed, paraffin embedded tissue sections were performed
by a labelled biotin-streptavidin method using 3-amino-
ethylcarbazole as chromogen. Four µ m tissue sections were
mounted on Superfrost/Plus slides. The mounted tissue sections
were deparaffinized by incubating the slides at 80˚C for 10 min,
immersed in heated oil, 60˚C (Estisol 312, Estichem A/S,
Denmark) and rehydrated through graded alcohols (99.9%, 97%
and 70%) to water. Antigen retrieval was performed using a
microwave TEG method by soaking the slides in TEG buffer, 10
mM TRIS, 0.5 mM EGTA pH 9.0. Then the slides were cooked for
12 min and cooled in the TEG buffer for 15 min. To ensure
blocking of endogeneous peroxidase activity the slides were
soaked in 1% H2O2 for 20 min, followed by three rinses in tap
water. The slides then were soaked in PBS buffer, 10 mM PO–4,
0.145 mM NaCl, pH 7.4 for 2 min. From this point and to the
development of the sections the descriptions given by the protocol
in the Mouse Immunohistochemistry Detection System, XHCO1,
Oncogene Science, Inc, UniTect™, Uniondale, NY were followed.
Briefly, non-specific protein binding was blocked by incubating
the sections with drops of normal horse serum for 20 min at room
temperature (RT). Then the slides were washed in PBS. Tissue
sections were incubated overnight at 4˚C with mouse monoclonal
antibodies against the MLH1 antibody (clone G168–15, 10 µ g/ml,
PharMingen, San Diego, CA), against the carboxyl terminal region
of the MSH2 antibody, (Ab-2, 3 µ g/ml) or against the PMS2 anti-
body (Ab-1, 7.5 µ g/ml). MSH2 and PMS2 were obtained from
Oncogene Research, Cambridge, MA. Before use, antibodies were
diluted in 1% BSA/PBS. After rinsing three times in PBS, the
slides were incubated with biotinylated secondary IgG for 30 min
at RT, followed by three rinses in PBS. Then sections were incu-
bated with the ABC reagent, (avidin and biotinlylated horseradish
peroxidase) for 30 min at RT, followed by a short rinse in PBS.
The slides were then washed in running tap water for 5 min and
developed in acetate buffer, 200 mM acetate, pH 5.0 containing 
3-amino-ethylcarbazole and 2.5 N, N dimethylformamide for 10
min. Shortly before use, 35% H2O2 was added. After developing,
the slides were washed in running tap water for 5 min. For counter-
staining Mayers haematoxylin was used. 
RT-PCR 
One µ g total RNA was used as starting material for first strand
cDNA synthesis. The synthesis was performed using the ‘First
strand cDNA synthesis kit’ from Pharmacia Biotech and 0.5 µ g of
random primers. The length of the amplicons were: β -actin 621
bp; hMSH3 439 bp; hPMS2 359 bp; hMSH6 288 bp; hMSH2 225
bp; hMLH1 215 bp; and hPMS1 174 bp. Primer sequences can be
obtained from the authors. One µ l of the 20 µ l cDNA reaction mix
was used in a 25 µ l PCR reaction. The PCR profile was one round
at 94˚C for 2 min followed by 29 rounds of 30s at 94˚C, 30 s at
62˚C and 45 s at 72˚C, followed by one final extension for 10 min
at 72˚C. Five µ l of the RT-PCR products were separated on a
ethidium bromide stained 2% agarose gel. The gel images were
saved as digitized images using the Eagle Eye II Still Video
System (Stratagene, California, USA). The areas of the bands were
calculated by The QGEL software version 1.72 (Kendrick Labs
Inc., Madison WI, USA) and normalized to β -actin. For all
samples to be tested, two independent RT-PCR reactions were
performed to ensure reproducibility. 
Determination of the mutation frequency at the Na+/K+
ATPase locus 
The mutation frequencies at the Na+/K+ ATPase locus were deter-
mined by plating HT1376, T24 and HCT15 cells in 1 µ M ouabain
(Sigma). For HT1376 and HCT15 3 × 106 cells were plated, and
for T24 6× 106 were plated. Cells were incubated for 2 weeks and
ouabain resistant colonies were visualized by staining with 0.5%
crystal violet in 50% methanol. Colonies of more than 50 cells
were counted (Umar et al, 1997). 
MTT assay 
The sensitivity to 1-methyl-3-nitro-1-nitrosoguanidine (MNNG,
Aldrich) was analysed by a MTT proliferation assay (Roche) in two
independent experiments in the MMR deficient bladder cancer line
T24 and compared to the MMR proficient bladder cancer line
HT1376 and the MMR deficient colon cancer cell line HCT15.
Cells were plated in 96-well plates at a density at 5 × 103 cells/well
and allowed to attach O/N. Prior to MNNG treatment cells were
treated for 1 h with 25 µ M O6-benzylguanine (Sigma) in serum free
media. MNNG treatment was carried out at different doses (0–
200 µ M) in serum free medium for 1 h. After treatment serum was
added to a final concentration of 10% and cells were incubated for
48 h. Then 20 µ l (5 mg/ml) MTT (3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide, Sigma) in PBS was added to each
well and then incubated for four hours. After this 100 µ l 10%
SDS/0.01 M HCL solution was added and incubated O/N. Plates
were read with absorbance at a wavelength of 570 nm and the back-
ground absorbance at 690 nm. 
RESULTS 
Mismatch repair in extracts from urothelial cell lines 
The seven bladder cancer cell lines selected for this study showed
varying degree of genomic instability ranging from nearly diploid,
to severe aneuploidy (Table 1). 
The lymphoblastoid cell line TK6, previously shown to be
mismatch repair proficient for both single base mismatches and
from one to sixteen base loops (Umar et al, 1994) was used as
positive control. All cell extracts used in the mismatch repair
assays were shown to be competent for SV40 T-antigen dependent
replication. The replication test was used to ensure that the extract
contained functional protein. As substrate for the in vitro
mismatch repair assay, we used M13mp2 substrates containing
either a G-G mismatch or a 2 base insertion-deletion loop in the
lacZ reporter gene, and a nick in the (–) strand 3′ to the mismatch,
to direct the mismatch repair reaction to the (–) strand. In both
cases, the (+) strand of the DNA encodes a colourless plaque
phenotype and the (–) strand encodes a blue plaque phenotype. Extracts of cell lines HCV29, HU609, SW780, RT4 and HT1376
all showed efficient strand-specific repair of both the G-G and 2
loop mismatch as indicated by a reduction in the mixed plaque
phenotype (Figure 1A) and a reduced blue/white ratio (not shown)
compared to mock treated control. The cell line J82 showed slightly
reduced repair of a 2-base loop (30%) (Figure 1A). In case of the
cell line T24, we found a more pronounced reduction in mismatch
repair capacity, G-G repair was reduced to 6% and 2 base loop
repair was reduced to 23% (Figure 1A). The reduced repair activity
of T24 was not due to a trans acting inhibitory factor, because
extract from T24 could not inhibit repair of a G-G mismatch when
mixed with extract from the repair proficient cell line TK6 (data not
shown). 
It is previously shown that the MSH6– cell line HCT15, is defi-
cient in repair of single base mismatches and one base loops, but
proficient for repair of larger loops (Drummond et al, 1995;
Lettieri et al, 1999). In a similar manner, the mismatch repair
capacity of the T24 extract is suggestive of MSH6 deficiency. We
therefore sequenced the coding region of the MSH6 gene in T24.
No mutations were observed in MSH6. We then also sequenced
the coding regions of the mismatch repair genes MLH1 and
MSH2. Again, no mutations were detected (data not shown). 
T24 is MNNG sensitive 
In two independent experiments no MNNG resistance could be
detected in the MMR deficient bladder cancer cell line T24 when
compared to the MMR proficient HT1376 (Figure 2). This indi-
cates functional MSH6 and/or MSH2 (Umar et al, 1997) as well 
as MLH1 (Aebi et al, 1997). 
Increased mutation frequency for T24 
To support the observed reduced MMR capasity for T24, we tried
to measure the mutation frequency at the HPRT locus.
Unfortunately, our attempts were unsuccessful, no HPRT mutant
clones were recovered in 5 × 106 cells. This indicates more than
one X chromosome expressing the HPRT gene. 
Instead we were able to measure mutation frequencies in the
Na+/K+ ATPase locus. Mutations in this locus result in resistance
to ouabain. T24 showed an increased mutation frequency of
>7.3-fold relative to the MMR proficient cell line HT1376. The
MSH6 deficient colorectal cancer cell line HCT15 had an
increase in mutation frequency relative to HT1376 of 53-fold
(Table 2). 
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Table 1
Cell line Karyotype Reference 
HCV29 Modal chromosome number = 49; XY, +der(2)t(2;5)(p?12;q?13), Ørntoft et al, 1996 
+3, del(4)(p?14), -5, -8, del(11)(p11.2;p14), add(11)(p?15),
del(12) (p11.1p12.1), add(14)(q?31), –17, +i(17q), add(20)(q13), +20.
HU609 Modal chromosome number = 57; XY, del(1)(p25),    Ørntoft et al, 1996 
+der(1)t(1;?)(q?22;?), del(2)(q31), +der(5)t(3;5)(p13;q32),
+6, del(7)(p11.2;p14), +7, –9, +10, +13, +14, +20, +add(20)(q13),
+der(20)t(3;20)(p?12.2;q13).
SW780 Modal chromosome number = 80 to 90 Kyriazis et al, 1984 
RT4 (P174) hyperdiploid and hypotetraploid to hypertetraploid with  Rigby et al, 1970 
abnormalities including dicentrics, breaks, translocations and minutes
HT1376 Modal chromosome number = 104 to 121 Rasheed et al, 1977 
J82 (P48) triploid with some tetraploid and hexaploid metaphases.  O’Toole et al, 1978 
Modal number = 72 including minute marker chromosomes
T24 Hypodiploidy to hypopentaploidy; stemline 86; 2 to 4 telocentrics; Fogh, 1978 
3 to 4 minutes, hypotetraploid to hypertetraploid with abnormalities 
including dicentrics, breaks, pulverization, minutes
and telocentric markers
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Figure 1 Mismatch repair measured in crude cell extracts from bladder
cancer cell lines and fresh tissue samples from transitional cell carcinomas.
The G-G mismatch and 2 base insertion/deletion loop substrates all
contained a single strand nick 3′ to the heteroduplex to direct the repair
reaction. A, mismatch repair efficiency of seven bladder cancer cell lines and
as positive control the lymphoblastoid cell line TK6. In most cases the
measured repair efficiency is an average of two individual experiments as
indicated by the error bars. B, mismatch repair efficiency in extract from
superficial pTa, submucosa invasive pT1 transitional cell carcinomas, and
one carcinoma in situ sample572 T Thykjaer et al 
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Microsatellite analysis 
In colon cancer, both the hereditary form, known as HNPCC, and
the sporadic form, it is known that there is a close correlation
between loss of function of the mismatch repair system and
microsatellite instability (Fishel et al, 1993; Genuardi et al, 1998;
Børresen et al, 1995). We chose four dinucleotide repeats, previ-
ously used for microsatellite instability analysis in bladder cancer
samples (Christensen et al, 1998), as well as one mononucleotide-
and one tetranucleotide repeat. The cell line T24 was tested for
microsatellite instability in these six microsatellite loci. None of
the tested loci showed instability. The results indicate that the
remaining repair capacity in T24 is sufficient to maintain
microsatellite stability, although it can not be ruled out that
analysis of more microsatellites would reveal unstable loci. 
Western blot analysis 
As a supplement to the RT-PCR analysis, the presence of the
proteins MSH2, MLH1 and PMS2 were investigated by Western
blotting using protein extract from T24 and as positive control
TK6. The three proteins were detected in both extracts (Figure 3). 
Mismatch repair in extracts from clinical samples 
As a novel approach, we also measured mismatch repair activity in
extracts of clinical specimens. We prepared extracts from transi-
tional cell carcinoma samples obtained fresh from surgery. The
patient we used for carcinoma in situ material, has been followed
for years and had widespread lesions in the bladder. We first tested
the extracts’ ability to perform SV40 T-antigen dependent replica-
tion. Only replication proficient extracts were used in the
mismatch repair assay. These extracts were tested for their ability
to repair a G-G mismatch and a 2-base insertion-deletion loop.
Extracts from the two stage pTa samples showed repair activity,
whereas extracts from the two-stage pT1 and the carcinoma in situ
sample showed lack of repair activity (Figure 1B). 
Immunohistochemical analysis 
Paraffin embedded tissue sections from the clinical samples used
in this study were used in immunostaining experiments using anti-
bodies against MSH2, MLH1 and PMS2. Due to the low amount
of tissue available from sample 1000 it was not possible to make
immunohistochemical analysis on this sample. Strong staining for
all three proteins was observed in all the clinical samples tested
(Figure 4). 
RT-PCR analysis 
Repair of the G-G mismatch used here is known to be initiated by
binding of the MSH2-MSH6 heterodimer to the mismatch. The
absence of coding sequence mutations in either MSH2 or MSH6 in
the T24 cell line suggests that the defect in G-G mismatch repair is
due to some other defect. One possibility is imbalanced expression
of mismatch repair genes. For example, two studies (Drummond 
et al, 1997; Marra et al, 1998) have shown that expression of excess
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Figure 2 Examination of MNNG resistance of the cell lines HCT15, HT1376
and T24. Similar results were obtained in two independent experiments. See
insets for key to symbols
Table 2 Mutation frequencies at the Na+/K+ ATPase locus 
Cell line Mutation frequency Relative mutation frequencya
HT1376 < 3 × 10–7 1 
T24 22 × 10–7 > 7.3 
HCT15 160 × 10–7 > 53 
aMeasured relative to HT1376. 
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Figure 3 Western blotting analysis of MLH1, MSH2 and PMS2 in the cell
line T24. As positive control the mismatch repair proficient cell line TK6 was
used. Each lane contains 10 µ g of crude cell extract similar to the extract
used in the mismatch repair assays. All three proteins were detected in both
cell lines, although the analysis indicate a reduced amount of MLH1 in T24
compared to TK6
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Figure 4 Examples from the immunohistochemical staining for PMS2,
MSH2 and MLH1. 901 is a repair proficient pTa bladder tumour. 351 is repair
deficient pT1 tumour. In all cases we could detect positive staining. Sample
901 was stained with antibodies against PMS2 (A), MSH2 (C) and MLH1 (E).
Sample 351 was stained with antibodies against PMS2 (B), MSH2 (D) and
MLH1 (F)Investigation of mismatch repair in bladder cancer 573
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MSH3 leads to reduced base-base mismatch repair capacity. This
defect is suggested to result from formation of excess MSH2-
MSH3 complex (which does not repair base-base mismatches)
with consequent reduction in the level of the MSH2-MSH6
complex that is needed for base-base mismatch repair. Therefore,
possible loss of expression or severe changes in expression ratios
between the six known mismatch repair genes, MSH2, MSH3,
MSH6, PMS1, PMS2 and MLH1 was investigated by RT-PCR
(Figure 5A). The analysis was performed on RNA extracted from
the seven bladder cancer cell lines used in the mismatch repair
assay, two microsatellite unstable colorectal cancer cell lines,
seven normal bladder biopsies, five low stage (pTa) and five high
stage (pT1-4) bladder cancer tissue samples. The tissue samples
877, 901 and 351 used in the mismatch repair assay were included
in the RT-PCR analysis. We could detect PCR products indicating
expression of the six mismatch repair genes in all the cell lines and
clinical samples investigated (Figure 5). We also tested if we could
detect changes in expression ratios between the individual
mismatch repair genes. We looked for changes in the expression
ratio between MSH3 and MSH6 which compete for binding to
MSH2, as well as ratio changes in expression between the two
components of the mutLα heterodimer complex, PMS2 and
MLH1. The PCR reactions were performed by the use of 29 cycles
which minimizes the plateau effect of amplification. The intensi-
ties of each of the PCR amplicons were analysed by densitometry
and normalized to β -actin (Figure 5B). The ratios between the indi-
vidual amplicons were found to be highly reproducible. The results
indicated a general upregulation of the mismatch repair genes in all
cell lines and bladder tumor samples compared to normal urothe-
lium. In the bladder cancer cell lines and the two colorectal cancer
cell lines, a significant difference from normal urothelium was
observed in the PMS2/MLH1 ratio (P < 0.004) (Figure 5C).
Notably, among the cell lines examined, T24 had the lowest level
of expression of MSH2 and MSH6 (arrows in Figure 5B), but a
somewhat higher relative level of expression of MSH3. This results
in modest changes in the relative ratios of the three mutS homologs
(arrows in Figure 5C). Also seen was a relative increase in MSH6
and PMS2 expression compared to MSH3 and MLH1
in invasive pT1-4 bladder tumours. The ratios between
MSH3/MSH6, MSH2/MSH3, MSH2/MSH6 and PMS2/MLH1
were then calculated (Figure 5C). Using this set-up we could detect
a significant reduction in MSH3/MSH6 expression ratio from
normal bladder urothelium to high stage tumours (P < 0.004) as
well as increase in MSH2/MSH3 ratio (P < 0.012), and
PMS2/MLH1 ratio (P < 0.005). 
DISCUSSION 
In this study we have investigated the postreplicative mismatch
repair system in bladder cancer cell lines and bladder cancer tissue
samples. Different methodological approaches were used to
analyse the functional status of the mismatch repair system. We
combined a functional in vitro assay, measurement of mutation
frequencies, microsatellite analysis, Western blotting, immunohis-
tochemistry and RT-PCR in our attempt to reveal possible explana-
tions for the missing or reduced mismatch repair activity we
observed in a subset of the samples tested. 
One of the seven bladder cancer cell lines, T24, showed signifi-
cantly reduced repair capacity of a G-G mismatch and, to a lesser
extent, reduced repair of a 2-loop substrate. In support of this
observation we revealed a >7-fold increase in the mutational
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Figure 5 RT-PCR analysis of the expression of the mismatch repair genes
MSH2, MSH3, MSH6, PMS1, PMS2 and MLH1. A, shows an example of a
gel image used for densiometric analysis. Five µ l of the PCR products were
loaded on a 2% agarose gel. B, Graphic presentation of the densiometric
analysis. The figure shows the relative band intensities from seven normal
bladder, five pTa, five pT1-4 and seven bladder cancer cell lines, normalized
to β -actin. Arrows indicate the measured relative band intensities for the cell
line T24. C, the ratio between the band intensities of MSH3/MSH6,
MSH2/MSH3, MSH2/MSH6 and PMS2/MLH1 for normal urothelium, stage
pTa, stage pT1-4 and bladder cancer cell lines were calculated and plotted.
Arrows indicate the ratios measured for the cell line T24574 T Thykjaer et al 
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frequency at the Na+/K+ ATPase locus relative to the MMR profi-
cient cell line HT1376. In comparison, the MSH6 deficient
colorectal cancer cell line HCT15 showed >53-fold higher muta-
tion frequency compared to HT1376. The RT-PCR analysis of T24
showed the presence of mRNA from all the six known human
MMR genes, MSH2-3-6, MLH1, PMS1-2. However, among the
seven bladder cancer cell lines examined, T24 had the lowest level
of expression of MSH2 and MSH6 and a somewhat higher relative
level of expression of MSH3. The resulting modest changes in the
relative ratios of the three mutS homologs offers one possible
explanation for the loss of G-G mismatch repair capasity but
retention of microsatellite stability and partial capasity to repair 
a substrate containing a 2-base insertion/deletion mismatch. 
This could reflect reduced activity of the MSH2-MSH6
heterodimer (required for repair of base-base but not
insertion/deletion mismatches), due to an imbalance in protein
levels that allows formation of MSH2-MSH3 complex in excess
over MSH2-MSH6 complex. Two previous studies have shown
that changes in ratio between MSH3 and MSH6, which both
compete for heterodimerization with MSH2, influence mismatch
repair activity (Drummond et al, 1997; Marra et al, 1998).
Alternatively, the reduced MMR activity might be due a mutation
in an unknown MMR gene. The two MMR deficient colorectal
cancer cell lines HCT15 and HCT116 showed a relative expression
pattern similar to the bladder cancer cell lines. Since T24 cells
show severe aneuploidy (Table 1), it is also possible that loss and
gain of chromosomal regions could influence the expression level
of genes acting further downstream in the repair reaction for
example exonucleases, helicases, ligases etc. The MMR phenotype
of T24 has similarities to a previously described repair deficient
Werner Syndrome fibroblast cell line PSV811 (Bennett et al,
1997), in the way that complementation experiments with a panel
of MMR deficient cell lines revealed that PSV811 was not defi-
cient in any of the known MMR genes and furthermore no
microsatellite instability was observed. 
In this report we also describe functional MMR analysis of five
extracts derived from clinical bladder cancer samples obtained
fresh from surgery. The composition of the samples was two Ta
benign papillomas, two submucosa invasive T1 papillomas, and
one sample obtained from a bladder with carcinoma in situ. 
The two benign Ta papillomas were repair proficient for both a
G-G mismatch and a 2 loop substrate. In contrast the two T1 papil-
lomas and the carcinoma in situ sample showed repair activities
less than 10% for both a G-G and two loop substrate. The
microsatellite analysis revealed no microsatellite instability in the
three repair deficient samples analysing nine microsatellite loci
(data not shown). We searched for explanations for the observed
lack of, or severely reduced mismatch repair activity in the two T1
and the one carcinoma in situ clinical samples. It was not possible
to make further investigations of sample 1000 due to the small
amount of tissue available. In the samples 351 and 889 we showed,
by immunostaining of tissue sections, that the gene products of
MLH1, PMS2 and MSH2 were present. We could measure a
significant reduction in the MSH3/MSH6 expression ratio (P <
0.004) in high stage tumours compared to normal bladder urothe-
lium, as well as increase in MSH2/MSH3 ratio (P < 0.012), and
PMS2/MLH1 ratio (P < 0.005). The latter change in ratio of mutL
homologs is also of interest, since a recent report (Shcerbakova
and Kunkel, 1999) showed that over-expression of MLH1 in yeast
resulted in a mutator phenotype. Further investigations will be
required to determine if a change in ratio of the mismatch repair
gene products is causing the observed lack of mismatch repair
activity in three of the clinical samples. One mechanism leading to
altered ratios could be the frequent genomic losses and gains
observed in bladder cancer by comparative genomic hybridization
analysis (Kallioniemi et al, 1995; Mahdy et al, 1999; Simon et al,
1998; Voorter et al, 1995). A characteristic observation in bladder
cancer is a high mutation rate, exemplified by mutations of the
TP53 which is mutated in approximately 1/3–1/2 of all tumours.
We speculate that a link might exist between the high mutation
rate and the observed lack of or reduced repair activity in the three
clinical samples and the cell line T24. 
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